![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Powerwave Technologies, Inc. (MM) | NASDAQ:PWAV | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.06 | 0 | 01:00:00 |
CALCULATION OF REGISTRATION FEE
Title of Each Class of Securities Offered |
Maximum Aggregate Offering Price |
Amount of Registration Fee(1) |
||
Global Medium-Term Notes, Series A |
$30,000,496.80 | $4,092.07 |
(1) | Calculated in accordance with Rule 457(r) of the Securities Act of 1933. |
Pricing Supplement dated October 26, 2012 to the YEELDS ® Product Supplement dated May 27, 2011 to the Prospectus Supplement dated May 27, 2011 and the Prospectus dated August 31, 2010 |
Filed Pursuant to Rule 424(b)(2) Registration No. 333-169119 |
$30,000,496.80 YEELDS ®
BARCLAYS BANK PLC
GLOBAL MEDIUM-TERM NOTES, SERIES A
Yield Enhanced Equity Linked Debt Securities (YEELDS ® ) Due December 31, 2012
Performance Linked to the Common Stock of Apple Inc., Series Number E-[ ]
Because these notes are part of a series of Barclays Bank PLCs debt securities called Global Medium-Term Notes, Series A, this pricing supplement and the accompanying product supplement, dated May 27, 2011 (the YEELDS ® product supplement) should also be read with the accompanying prospectus supplement, dated May 27, 2011 relating to Barclays Bank PLCs Global Medium-Term Notes, Series A (the prospectus supplement) and the accompanying prospectus dated August 31, 2010 (the base prospectus). Terms used here have the meanings given them in the YEELDS ® product supplement, the prospectus supplement or the base prospectus, unless the context requires otherwise.
Common stock issuer : Apple Inc.. Apple Inc. is not involved in this offering and has no obligation with respect to the notes.
Common stock : The common stock of the common stock issuer listed on the NASDAQ Global Select Market under the ticker symbol AAPL.
Number of YEELDS ® : 50,574.
Principal amount : $593.20 per note, and, in the aggregate, $30,000,496.80.
Inception Date : October 26, 2012
Issue Date : October 31, 2012
Stated maturity date : December 31, 2012, subject to postponement if the valuation date is postponed. If the stated maturity date is not a business day, any payment required to be made on the stated maturity date will instead be made on the next business day, with the same effect as if paid on the scheduled stated maturity date, as described in the section entitled Description of the NotesPayment at maturity in the YEELDS ® product supplement.
Valuation date : December 26, 2012, subject to postponement if a market disruption event occurs or if such a day is not a scheduled trading day, as described in the section entitled Description of the NotesPayment at maturitySettlement value in the YEELDS ® product supplement.
Interest rate : 8.65% per annum.
Interest payment dates : Monthly, on the 30 th day of each month during the term of the notes, beginning on November 30, 2012, and ending on and including the stated maturity date.
Interest payment record dates : 15 calendar days prior to each interest payment date.
Initial value : $593.20, which is the average execution price per share for the common stock that an affiliate of Barclays Bank PLC has paid to hedge Barclays Bank PLCs obligations under the notes.
Equity cap price : $652.5200, which is 110.00% of the initial value.
Payment at maturity : On the stated maturity date, Barclays Bank PLC will pay you, per note, the lesser of:
(1) | the conversion value; and |
(2) | the equity cap price. |
Conversion value: The conversion value, per note, will equal the product of:
(1) | the settlement value; times |
(2) | the conversion ratio. |
Conversion ratio: 1.0, reflecting the number of shares of the underlying common stock to which each note is exposed.
Settlement value : The settlement value will be based upon the product of the adjusted closing price of the common stock on the valuation date, times the multiplier then in effect on the valuation date, and shall generally be equal to such product.
Multiplier : The multiplier will initially be 1.0, subject to adjustment under various circumstances as described in the YEELDS ® product supplement in Description of the NotesAdjustments to multipliers and to securities included in the calculation of the settlement value.
Adjusted closing price : The adjusted closing price of the common stock on any scheduled trading day is the sum of:
(1) | the closing price of the common stock on such scheduled trading day; and |
(2) | its dividend adjustment amount on such scheduled trading day. |
Closing price : The last reported sales price for the common stock on the NASDAQ Global Select Market at the scheduled weekday closing time of the regular trading session of the NASDAQ Global Select Market.
Dividend adjustment amount : The dividend adjustment amount as of any scheduled trading day will be calculated as the difference between the actual aggregate dividend and the expected aggregate dividend, in each case as of such scheduled trading day, which difference may be positive, zero or negative.
Actual aggregate dividend : With respect to any scheduled trading day, the actual aggregate dividend shall be calculated as follows:
|
if ex-dividend dates occur within the period from, but excluding, the Inception Date to, and including, such scheduled trading day, the actual aggregate dividend shall be the sum of declared cash dividends corresponding to all such ex-dividend dates per share of the common stock; |
|
if no ex-dividend dates occur within the period from, but excluding, the Inception Date to, and including, such scheduled trading day, the actual aggregate dividend shall be zero. |
Expected aggregate dividend: With respect to any scheduled trading day, the expected aggregate dividend shall be calculated as the sum of the expected dividend amounts corresponding to all expected ex-dividend dates within the period from, but excluding, the Inception Date to, and including, such scheduled trading day.
Expected dividend schedule: The expected dividend schedule for the common stock is as follows:
Expected Ex-Dividend Date |
Expected Adjusted Dividends (per Share) |
|
November 7, 2012 |
$2.65 |
Stock settlement option : Yes; if Barclays Bank PLC has elected to exercise the stock settlement option, on the stated maturity date, Barclays Bank PLC will deliver to you a number of shares of the common stock equal to (1) the total cash value of payment due at maturity on the number of notes you own, divided by (2) the closing price of such common stock on the valuation date, all as described below in the section entitled Stock Settlement Option and will provide the trustee with not less than three business days prior written notice of such election.
Postponement of the valuation date because of a market disruption event : If a market disruption event occurs on the valuation date, as set forth in this document, such valuation date will be postponed until the next scheduled trading day on which no market disruption event occurs; provided, however, if a market disruption event occurs on each of the eight scheduled trading days following the originally scheduled valuation date, then (a) that eighth scheduled trading day shall be deemed to be such valuation date and (b) the calculation agent shall determine the closing price of the common stock for that eighth scheduled trading day, based upon its good faith estimate of the closing price on such day.
Denominations : $593.20 and integral multiples thereof.
Listing : The notes will not be listed on any exchange.
CUSIP: 06741LAB0
ISIN: US06741LAB09
See Risk Factors sections beginning on page PR-10 of the YEELDS ® product supplement and beginning on page S-6 of the prospectus supplement for a description of risks relating to an investment in the Notes.
We may use this pricing supplement in the initial sale of YEELDS ® . In addition, Barclays Capital Inc. or another of our affiliates may use this pricing supplement in market resale transactions in any YEELDS ® after their initial sale. Unless we or our agent informs you otherwise in the confirmation of sale, this pricing supplement is being used in a market resale transaction.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this pricing supplement, any accompanying YEELDS ® product supplement or any accompanying prospectus supplement or base prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
YEELDS ® constitute our direct, unconditional, unsecured and unsubordinated obligations and are not deposit liabilities of Barclays Bank PLC and are not insured by the United States Federal Deposit Insurance Corporation or any other governmental agency of the United States, the United Kingdom or any other jurisdiction.
Price to Public |
Agents Commission |
Proceeds to
|
||||
Per Note |
100% | 0% | 100% | |||
Total |
$30,000,496.80 | $0.00 | $30,000,496.80 |
Please see Supplemental Plan of Distribution in this pricing supplement for more information.
YEELDS ® is a registered trademark of Barclays Capital Inc.
Barclays Bank PLC has filed a registration statement (including a base prospectus) with the U.S. Securities and Exchange Commission, or SEC, for this offering. Before you invest, you should read this pricing supplement together with the base prospectus, as supplemented by the prospectus supplement relating to our Series A medium-term notes of which the notes are a part and the YEELDS ® product supplement. Purchasers should rely upon the base prospectus, the prospectus supplement, the YEELDS ® product supplement, this pricing supplement, any other relevant terms supplement and any relevant free writing prospectus for complete details. This pricing supplement, together with the documents listed below, contains the terms of the notes and supersedes all prior or contemporaneous communications concerning the notes. To the extent that there are any inconsistencies among the documents listed below, this pricing supplement shall supersede the YEELDS ® product supplement, which shall, likewise, supersede the base prospectus and the prospectus supplement. You should carefully consider, among other things, the matters set forth in Risk Factors in the accompanying YEELDS ® product supplement as the notes involve risks not associated with conventional debt securities. We urge you to consult your investment, legal, tax, accounting and other advisors before you invest in the notes. You may get these documents and other documents Barclays Bank PLC has filed for free by searching the SEC online database at www.sec.gov, with Barclays Bank PLC as a search term or through the links below, or by emailing Barclays Bank PLC at us.syndicate.ops@barcap.com.
You may access these documents on the SEC website at www.sec.gov as follows (or if such address has changed, by reviewing our filings for the relevant date on the SEC website):
|
YEELDS ® product supplement dated May 27, 2011: |
http://www.sec.gov/Archives/edgar/data/312070/000119312511152968/d424b3.htm
|
Prospectus supplement dated May 27, 2011: |
http://www.sec.gov/Archives/edgar/data/312070/000119312511152766/d424b3.htm
|
Base prospectus dated August 31, 2010: |
http://www.sec.gov/Archives/edgar/data/312070/000119312510201448/df3asr.htm
If a market disruption event occurs on a day that would otherwise be the valuation date, there will be a delay in settlement of the notes.
If a market disruption event occurs on a day that would otherwise be the valuation date, settlement of the notes will be delayed, depending on the circumstances surrounding the market disruption event, for up to eight scheduled trading days for the postponed valuation date following the stated maturity date.
Postponement of the valuation date may result in a reduced amount payable at maturity.
As the payment at maturity is a function of, among other things, the adjusted closing price of common stock. The postponement of the valuation date may result in the application of a different adjusted closing price, and, accordingly, decrease the payment you receive at maturity.
The tax consequences are uncertain.
The U.S. federal income tax treatment of the notes is uncertain and the Internal Revenue Service could assert that the notes should be taxed in a manner that is different than described herein. As discussed further in the accompanying product supplement, the Internal Revenue Service issued a notice in 2007 indicating that it and the Treasury Department are actively considering whether, among other issues, you should be required to accrue interest over the term of an instrument such as the notes at a rate that could potentially exceed the interest paid currently on the notes and whether all or part of the gain you may recognize upon the sale or maturity of an instrument such as the notes could be treated as ordinary income. Similarly, the Internal Revenue Service and the Treasury Department have current projects open with regard to the tax treatment of pre-paid forward contracts, contingent notional principal contracts and other derivative contracts. While it
PS-3
is impossible to anticipate how any ultimate guidance would affect the tax treatment of instruments such as the notes (and while any such guidance may be issued on a prospective basis only), such guidance could be applied retroactively and could in any case increase the likelihood that you will be required to accrue income at a rate that may exceed the payments you receive on the notes. The outcome of this process is uncertain. In addition, any character mismatch arising from your inclusion of ordinary income and capital loss (if any) upon the sale or maturity of your notes may result in adverse tax consequences to you because an investors ability to deduct capital losses is subject to significant limitations. You should consult your tax advisor as to the possible alternative treatments in respect of the notes.
POSTPONEMENT OF THE VALUATION DATE BECAUSE OF A MARKET DISRUPTION EVENT
If a market disruption event occurs on a day that would otherwise be the valuation date, as set forth on the cover page of this pricing supplement, such valuation date will be postponed until the next scheduled trading day on which no market disruption event occurs; provided, however, if a market disruption event occurs on each of the eight scheduled trading days following the originally scheduled valuation date, then (a) that eighth scheduled trading day shall be deemed to be that valuation date and (b) the calculation agent shall determine the adjusted closing price of the common stock for that eighth scheduled trading day, based upon its good faith estimate of the value of the common stock as of the close of trading on the relevant exchange on such day.
EXAMPLES OF AMOUNT PAYABLE AT MATURITY
Here are three examples of the amount that may be payable on the stated maturity date. In each of these examples it is assumed that (1) the actual aggregate dividend of the common stock equals its expected aggregate dividend as of the valuation date and (2) the multiplier has not been adjusted.
Example 1. Assuming the settlement value is $400.00 after applying the initial multiplier:
As a result, because the settlement value of 400.00 is less than $652.5200, on the stated maturity date, you would receive $400.00 per note, plus any accrued but unpaid interest payments.
In the case of stock settlement in this example, you would receive on the stated maturity date a number of shares of the common stock equal to (1) the total cash value of payment due at maturity on the number of notes you own, divided by (2) the closing price of the common stock on the valuation date.
Accordingly you would receive on the stated maturity date, if you held one note, 1 share of the common stock, plus any accrued but unpaid interest payments. To the extent that you hold more than one note, the calculations of cash payments in lieu of fractional shares would be made on an aggregate, rather than on a per note, basis. For example, if you held 50,574 notes, you would receive on the stated maturity date in total, 50,574 shares of the common stock plus accrued but unpaid interest payments.
Example 2. Assuming the settlement value is $650.00 after applying the initial multiplier:
As a result, because the settlement value of $650.00 is less than $652.5200, on the stated maturity date, you would receive $650.00 per note, plus any accrued but unpaid interest payments.
In the case of stock settlement in this example, you would receive on the stated maturity date a number of shares of the common stock equal to (1) the total cash value of payment due at maturity on the number of notes you own, divided by (2) the closing price of the common stock on the valuation date.
Accordingly you would receive on the stated maturity date, if you held one note, 1 share of the common stock, plus any accrued but unpaid interest payments. To the extent that you hold more than one note, the calculations of cash payments in lieu of fractional shares would be made on an aggregate, rather than on a per note, basis. For example, if you held 50,574 notes, you would receive on the stated maturity date in total, 50,574 shares of the common stock plus accrued but unpaid interest payments.
PS-4
Example 3. Assuming the settlement value is $700.00 after applying the initial multiplier:
As a result, because the settlement value of $700.00 is greater than $652.5200, on the stated maturity date, you would receive $652.5200 per note, plus any accrued but unpaid interest payments.
In the case of stock settlement in this example, you would receive on the stated maturity date a number of shares of the common stock equal to (1) the total cash value of payment due at maturity on the number of notes you own, divided by (2) the closing price of the common stock on the valuation date.
Accordingly, if you held one note, you would receive on the stated maturity date $652.5200 in cash, plus any accrued but unpaid interest payments, and you would not receive any shares of the common stock. To the extent that you hold more than one note, the calculations of cash payments in lieu of fractional shares would be made on an aggregate, rather than on a per note, basis. For example, if you held 50,574 notes, you would receive on the stated maturity date in total, 47,143 shares of the common stock plus $446.48 in cash, plus accrued but unpaid interest payments.
To the extent the actual settlement value differs from the values assumed above or that the actual aggregate dividend of the common stock differs from its expected aggregate dividend as of the valuation date, the results indicated above would be different.
If the stock settlement option is elected, the market price of the shares of Apple Inc. that you receive per note on the stated maturity date may be less than the amount that you would have received had the stock settlement option not been elected because the number of shares you receive will ordinarily be calculated based upon the adjusted closing price of Apple Inc.s common stock on the valuation date.
STOCK SETTLEMENT OPTION
If Barclays Bank PLC elects to exercise its stock settlement option and Barclays Bank PLC provides the trustee not less than three business days prior written notice of such election, Barclays Bank PLC will, subject to the next paragraph, deliver on the stated maturity date a number of shares of the common stock equal to (1) the total cash value of payment due at maturity on the number of notes you own, divided by (2) the closing price of the common stock on the valuation date.
If, however Barclays Bank PLC determines that it is prohibited from delivering such shares, or that it would otherwise be unduly burdensome to deliver such shares, on the stated maturity date, it will pay in cash the amount payable at maturity as if it had not elected the stock settlement option.
If the calculation above results in a fractional share, Barclays Bank PLC will pay cash to you in an amount equal to that fractional share, based upon the adjusted closing price of the common stock (and any other equity securities included in the calculation of the settlement value) on the valuation date.
Upon the occurrence of certain events, or if Apple Inc. is involved in certain extraordinary transactions, the number of shares of Apple Inc. to be delivered may be adjusted and Barclays Bank PLC may deliver, in lieu of or in addition to Apple Inc.s common stock, cash and any other equity securities used in the calculation of the settlement value, all as determined by the calculation agent. See Description of the NotesAdjustments to multipliers and to securities included in the calculation of the settlement value in the accompanying YEELDS ® product supplement.
Because the settlement value will ordinarily be determined on the valuation date, if Barclays Bank PLC elects the stock settlement option, the effect to holders will be as if the notes matured on the valuation date (subject to postponement as described above in the section entitled Postponement of the Valuation Date, because of a Market Disruption Event). Thus, the aggregate value of the shares of Apple Inc.s common stock and any other equity securities and cash that you receive at maturity may be more or less than the amount you would have received had Barclays Bank PLC not elected the stock settlement option as a result of fluctuations in the value of these securities during the period between the valuation date and the maturity
PS-5
date. Consequently, it is possible that the aggregate value of the cash and securities that you receive at maturity may be less than the payment that you would have received at maturity had Barclays Bank PLC not elected to settle the notes with shares of Apple Inc.s common stock. In the absence of any election notice to the trustee, Barclays Bank PLC will be deemed to have elected to pay the amount payable at maturity in cash.
PS-6
COMMON STOCK ISSUER AND COMMON STOCK
Apple Inc.
According to publicly available information, Apple Inc. and its subsidiaries (collectively, the Company) design, manufacture and market mobile communication and media devices, personal computers, and portable digital music players, and sell a variety of related software, services, peripherals, networking solutions, and third-party digital content and applications. The Company sells its products through its retail and online stores, as well as through its direct sales force and third-party cellular network carries, wholesalers and retailers.
Information filed by the Company with the SEC under the Exchange Act can be located by reference to its SEC file number: 000-10030, or its CIK Code: 0000320193. The Companys Class A common stock is listed on the NASDAQ Global Select Market under the ticker symbol AAPL.
Information from outside sources is not incorporated by reference in, and should not be considered part of, this pricing supplement or the accompanying prospectus or prospectus supplement. We make no representation or warranty as to the accuracy or completeness of the information contained in outside sources.
Historical information about the common stock
The following table presents the high and low closing prices for the common stock, as reported on Apple Inc. during each fiscal quarter in 2007, 2008, 2009, 2010, 2011 and 2012 (through October 26, 2012), and the closing price at the end of each quarter in 2007, 2008, 2009, 2010, 2011 and 2012 (through October 26, 2012).
The historical prices of the common stock are not necessarily indicative of future performance; accordingly, there can be no assurance that the payment you receive at maturity will equal or exceed the principal amount. The historical prices below have been adjusted to reflect any stock splits or reverse stock splits.
All information in the table that follows was obtained from Bloomberg L.P., without independent verification. The historical performance of the linked share should not be taken as an indication of the future performance of the share during the term of the Notes.
PS-7
High | Low | Period End | ||||||||||||
2007 |
||||||||||||||
First Quarter | $ | 97.13 | $ | 83.27 | $ | 92.91 | ||||||||
Second Quarter | $ | 125.09 | $ | 90.24 | $ | 122.04 | ||||||||
Third Quarter | $ | 154.50 | $ | 117.05 | $ | 153.54 | ||||||||
Fourth Quarter | $ | 199.83 | $ | 153.76 | $ | 198.08 | ||||||||
2008 |
||||||||||||||
First Quarter | $ | 194.97 | $ | 119.15 | $ | 143.50 | ||||||||
Second Quarter | $ | 189.96 | $ | 147.14 | $ | 167.44 | ||||||||
Third Quarter | $ | 179.69 | $ | 105.26 | $ | 113.66 | ||||||||
Fourth Quarter | $ | 111.04 | $ | 80.49 | $ | 85.35 | ||||||||
2009 |
||||||||||||||
First Quarter | $ | 109.87 | $ | 78.20 | $ | 105.12 | ||||||||
Second Quarter | $ | 144.67 | $ | 108.69 | $ | 142.43 | ||||||||
Third Quarter | $ | 186.15 | $ | 135.40 | $ | 185.37 | ||||||||
Fourth Quarter | $ | 211.64 | $ | 180.76 | $ | 210.86 | ||||||||
2010 |
||||||||||||||
First Quarter | $ | 235.83 | $ | 192.00 | $ | 234.93 | ||||||||
Second Quarter | $ | 274.16 | $ | 235.86 | $ | 251.53 | ||||||||
Third Quarter | $ | 292.46 | $ | 240.16 | $ | 283.75 | ||||||||
Fourth Quarter | $ | 325.47 | $ | 278.64 | $ | 322.56 | ||||||||
2011 |
||||||||||||||
First Quarter | $ | 363.13 | $ | 326.72 | $ | 348.45 | ||||||||
Second Quarter | $ | 353.10 | $ | 315.32 | $ | 335.67 | ||||||||
Third Quarter | $ | 413.45 | $ | 343.23 | $ | 381.18 | ||||||||
Fourth Quarter | $ | 422.24 | $ | 363.50 | $ | 405.00 | ||||||||
2012 |
||||||||||||||
First Quarter | $ | 617.62 | $ | 411.23 | $ | 599.47 | ||||||||
Second Quarter | $ | 636.23 | $ | 530.12 | $ | 584.00 | ||||||||
Third Quarter | $ | 702.10 | $ | 574.88 | $ | 667.26 | ||||||||
Fourth Quarter (through October 26, 2012) | $ | 671.74 | $ | 604.00 | $ | 604.00 |
PS-8
HYPOTHETICAL RETURNS
The table below illustrates, for a range of hypothetical settlement values, in each case assuming that (a) the investment is held from the date on which the notes are first issued until the stated maturity date, (b) the actual aggregate dividend of the common stock equals its expected aggregate dividend as of the final valuation date and (c) that the multiplier has not been adjusted.
|
the hypothetical conversion value per note; |
|
the percentage change from the principal amount to the hypothetical conversion value; |
|
the total interest payments paid or payable on or before the stated maturity date per note; |
|
the hypothetical total amount payable per note on the stated maturity date; 1 |
|
the hypothetical total annualized yield on the note on the stated maturity date; 2 and |
|
the hypothetical total annualized yield from direct ownership of the common stock. |
1 |
Excludes accrued but unpaid interest payments payable on the stated maturity date. |
2 |
The hypothetical total annualized yield on the stated maturity date represents the interest rate per year used in determining the present values, discounted to the original issue date (computed on the basis of a 360-day year of twelve 30-day months compounded annually), of all payments made or to be made on the notes, including the amount payable on the stated maturity date and all interest payments through the stated maturity date, the sum of these present values being equal to the original issue price. |
PS-9
Hypothetical
value |
Hypothetical
value |
Percentage
change from the
to the hypothetical
|
Total interest
paid or payable on or before the stated maturity date |
Hypothetical
total amount
on the stated
|
Hypothetical
total annualized
note on the stated maturity date |
Hypothetical
total annualized
|
||||||
$118.64 |
$118.6400 | -80% | $8.5520 | $118.6400 | -99.99% | -99.99% | ||||||
$237.28 |
$237.2800 | -60% | $8.5520 | $237.2800 | -99.44% | -99.56% | ||||||
$355.92 |
$355.9200 | -40% | $8.5520 | $355.9200 | -93.66% | -95.12% | ||||||
$474.56 |
$474.5600 | -20% | $8.5520 | $474.5600 | -63.56% | -72.89% | ||||||
$593.20 |
$593.2000 | 0% | $8.5520 | $593.2000 | 44.68% | 2.71% | ||||||
$711.84 |
$711.8400 | 20% | $8.5520 | $652.5200 | 162.75% | 205.33% | ||||||
$830.48 |
$830.4800 | 40% | $8.5520 | $652.5200 | 162.75% | 667.48% | ||||||
$949.12 |
$949.1200 | 60% | $8.5520 | $652.5200 | 162.75% | 1606.02% | ||||||
$1,067.76 |
$1,067.7600 | 80% | $8.5520 | $652.5200 | 162.75% | 3352.19% |
The above figures are for purposes of illustration only. The actual amount received by investors and the resulting total annualized yield will depend entirely on the actual settlement value determined by the calculation agent. In particular, the actual settlement value could be lower or higher than those reflected in the table.
You should compare the features of the notes to other available investments before deciding to purchase the notes. Due to the uncertainty concerning the settlement value, the return on investment with respect to the notes may be higher or lower than the return available on other securities issued by Barclays Bank PLC or by others. You should reach an investment decision only after carefully considering the suitability of the notes in light of your particular circumstances.
PS-10
SUPPLEMENTAL MATERIAL TAX CONSIDERATIONS
The material tax consequences of your investment in the notes are summarized below. The discussion below supplements the discussion under Certain United States Federal Income Tax Consequences in the accompanying YEELDS ® product supplement and Certain U.S. Federal Income Tax Considerations in the accompanying prospectus supplement. Except as noted under Non-U.S. Holders below, this section applies to you only if you are a U.S. holder (as defined in the accompanying YEELDS ® product supplement) and you hold your notes as capital assets for tax purposes and does not apply to you if you are a member of a class of holders subject to special rules or are otherwise excluded from the discussion in the product supplement (for example, if you did not purchase your notes in the initial issuance of the notes).
The United States federal income tax consequences of your investment in the notes are uncertain and the Internal Revenue Service could assert that the notes should be taxed in a manner that is different than described below. Pursuant to the terms of the notes, Barclays Bank PLC and you agree, in the absence of a change in law or an administrative or judicial ruling to the contrary, to characterize your notes as a pre-paid income-bearing executory contract with respect to the common stock that is subject to tax as described herein. If your notes are so treated, you will likely be taxed on interest paid on the notes as ordinary income in accordance with your regular method of accounting for United States federal income tax purposes. In addition, it would be reasonable for you to recognize capital gain or loss upon the sale or cash-settlement upon maturity of your notes in an amount equal to the difference between the amount you receive at such time (excluding amounts attributable to interest) and your tax basis in the notes. Because the term of your notes will not exceed one year, such gain or loss should generally be short-term capital gain or loss. Short-term capital gains are generally subject to tax at the marginal tax rates applicable to ordinary income. Any character mismatch arising from your inclusion of ordinary income and short-term capital loss (if any) upon the sale or maturity of your notes may result in adverse tax consequences to you because an investors ability to deduct capital losses is subject to significant limitations. Moreover, in the event of physical settlement, such loss may be deferred (as described in the following paragraph).
If you receive shares upon the maturity of your notes pursuant to the stock settlement option, it is not clear whether the receipt of shares should be treated as (i) a taxable settlement of the notes followed by a purchase of the shares or (ii) a tax-free purchase of the shares pursuant to the original terms of the notes. Accordingly, you should consult your tax advisor about the tax consequences to you of receiving shares upon the maturity of your notes. If the receipt of the shares is treated as a taxable settlement of the notes followed by a purchase of the shares, you should (i) recognize capital gain or loss in an amount equal to the difference between the fair market value of the shares you receive at such time plus the cash received in lieu of a fractional share, if any, and your tax basis in the notes, and (ii) take a basis in such shares in an amount equal to their fair market value at such time. If, alternatively, the receipt of shares upon the maturity of your notes is treated as a tax-free purchase of the shares, (i) the receipt of shares upon maturity of your notes should not give rise to the current recognition of gain or loss at such time, (ii) you should take a carryover basis in such shares equal to the price you paid for your notes, less the basis attributable to a fractional share, if any, and (iii) if you receive cash in lieu of a fractional share upon the stock settlement of such notes, you should recognize short-term capital gain or loss equal to the difference between the amount of cash you receive and your tax basis in the fractional share. Your holding period in the shares you receive upon the maturity of your notes will begin on the day after you receive such shares.
In the opinion of our special tax counsel, Sullivan & Cromwell LLP, it would be reasonable to treat your notes in the manner described above. This opinion assumes that the description of the terms of the notes in this pricing supplement is materially correct.
As discussed further in the accompanying YEELDS ® product supplement, the Treasury Department and the Internal Revenue Service are actively considering various alternative treatments that may apply to instruments such as the notes, possibly with retroactive effect. In addition, the Internal Revenue Service could
PS-11
potentially assert that the dividend adjustment amount, if any, should be separately includable in ordinary income either upon receipt or over the term of the notes.
For a further discussion of the tax treatment of your notes as well as possible alternative characterizations, please see the discussion under the heading Certain United States Federal Income Tax Consequences in the accompanying YEELDS ® product supplement. You should consult your tax advisor as to the possible alternative treatments in respect of the notes. For additional, important considerations related to tax risks associated with investing in the notes, you should also examine the discussion about tax risks under Additional Risk Factors, in this pricing supplement.
Specified Foreign Financial Asset Reporting. Under legislation enacted in 2010, owners of specified foreign financial assets with an aggregate value in excess of $50,000 (and in some circumstances, a higher threshold) may berequired to file an information report with respect to such assets with their tax returns. Specified foreign financial assets include any financial accounts maintained by foreign financial institutions, as well as any of the following (which may include your notes), but only if they are not held in accounts maintained by financial institutions: (i) stocks and securities issued by non-U.S. persons, (ii) financial instruments and contracts held for investment that have non-U.S. issuers or counterparties and (iii) interests in foreign entities. Holders are urged to consult their tax advisors regarding the application of this legislation to their ownership of the notes.
Non-U.S. Holders . The U.S. federal income tax treatment of the notes is uncertain, and alternative treatments are possible. Under one such alternative treatment, the notes could be viewed as a notional principal contract. Legislation enacted in 2010 imposes a 30% withholding tax on any dividend equivalent payment made to a non-U.S. holder of a specified notional principal contract. It is possible, under the alternative characterization of the notes as a notional principal contract, that the Internal Revenue Service could assert that the notes should be treated as a specified notional principal contract that gives rise to payments subject to such withholding, particularly if the notes are stock settled. You should consult your tax advisor about this risk and other potential U.S. federal income tax risks associated with owning the notes.
Barclays currently does not withhold on interest payments to non-U.S. holders in respect of instruments such as the notes. However, if Barclays determines that there is a material risk that it will be required to withhold on any such payments, Barclays may withhold on any interest payments at a 30% rate, unless you have provided to Barclays (i) a valid Internal Revenue Service Form W-8ECI or (ii) a valid Internal Revenue Service Form W-8BEN claiming tax treaty benefits that reduce or eliminate withholding. If Barclays elects to withhold and you have provided Barclays with a valid Internal Revenue Service Form W-8BEN claiming tax treaty benefits that reduce or eliminate withholding, Barclays may nevertheless withhold up to 30% on interest payments it makes to you if there is any possible characterization of the payments that would not be exempt from withholding under the treaty. In addition, non-U.S. holders will be subject to the general rules regarding information reporting and backup withholding as described under the heading Certain U.S. Federal Income Tax Considerations Information Reporting and Backup Withholding in the accompanying prospectus supplement.
SUPPLEMENTAL PLAN OF DISTRIBUTION
We have agreed to sell to Barclays Capital Inc. (the Agent), and the Agent has agreed to purchase from us, the principal amount of the notes at the price specified on the cover of this pricing supplement. The Agent is committed to take and pay for all of the notes, if any are taken.
The Agent proposes to offer the notes initially at a public offering price equal to the price specified on the cover of this pricing supplement.
Delivery of the notes will be made against payment for the notes on or about the issue date indicated on the cover of this pricing supplement, which is the fifth business day following the inception date (that is, the notes will have a settlement cycle referred to as T+5). For a description of considerations in connection with notes that are issued on a day later than the third business day following the inception date, please see Plan of Distribution in the accompanying prospectus supplement.
PS-12
1 Year Powerwave Chart |
1 Month Powerwave Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions